Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diethazine is a phenothiazine derivative that was historically utilized as an antiparkinsonian agent. Unlike many other phenothiazines that primarily act as antipsychotics through dopamine receptor antagonism, diethazine exhibits potent anticholinergic (antimuscarinic) and antihistaminic properties. Developed by Rhône-Poulenc, it was one of the first synthetic compounds used to treat the tremors and rigidity associated with Parkinson's disease and drug-induced extrapyramidal syndromes. While it also possesses sedative and local anesthetic activities, its clinical use has been largely superseded by more effective and better-tolerated therapies such as levodopa and newer anticholinergic agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diethazine.